Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Rebus Holdings, Inc. (NSPX) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/16/2022 8-K Quarterly results
10/13/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
10/12/2021 8-K/A Other Events  Interactive Data
10/12/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock Split WESTLAKE VILLAGE, CA, October 12, 2021 – Inspyr Therapeutics, Inc. is announcing a 1-for-75 reverse stock split of its common stock and a holding company restructuring whereby Rebus Holdings, Inc. , a newly created entity will serve as the new holding company that will replace Inspyr as the public company trading on the OTC Markets trading under the symbol RBSH. The reverse stock split and holding company reorganization will occur concurrently. Inspyr has completed a restructuring consisting of reacquiring its rights to its now lead asset RT-AR001 and transforming into a holding company structure. Management believes that reacquiring the Adenosine assets and its new structure will lead to a more streamlined..."
06/21/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
11/27/2020 8-K Quarterly results
10/29/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Senior Convertible Debenture"
10/08/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
03/30/2020 8-K Other Events
03/06/2020 8-K Quarterly results
09/30/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
07/03/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Securities Purchase Agreement",
"Form of Senior Convertible Debenture"
12/21/2017 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Audited Financial Statements of Lewis & Clark Pharmaceuticals, Inc. for the years ended December 31, 2016 and 2015",
"Unaudited Financial Statements of Lewis & Clark Pharmaceuticals, Inc. for the six months ended June 30, 2017 and 2016",
"Unaudited Pro Forma Financial Statements of Inspyr Therapeutics, Inc. for the periods ended December 31, 2016 and June 30, 2017"
11/03/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2017 Equity Compensation Plan adopted November 1, 2017"
09/15/2017 8-K Quarterly results
09/12/2017 8-K Quarterly results
09/12/2017 8-K Quarterly results
08/03/2017 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "SECTION I",
"SHARE ESCROW AGREEMENT This SHARE ESCROW AGREEMENT dated as of this ____ day of July 2017 by and among INSPYR THERAPEUTICS, INC., a Delaware corporation , having an address at 31200 Via Colinas #200, Westlake Village, CA 91362, ROBERT D. THOMPSON, LARRY E. RODMAN, JOHN MONTGOMERY AND GRETCHEN MONTGOMERY, each individuals , each having address set forth on Schedule I hereto, and SILVESTRE LAW GROUP, P.C. , a California Professional Corporation, having an office at 31200 Via Colinas #200, Westlake Village, CA 91362. All capitalized terms not herein defined shall have the meaning ascribed to them in that certain Share Exchange Agreement, of even date herewith and as amended or supplemented from time-to-time, including all attachments, schedules and exhibits thereto . W I T N E S S E T H : WHE..."
04/24/2017 8-K Form 8-K - Current report
03/20/2017 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Certificate of Designation",
"Form of Series C Preferred Stock Certificate",
"Form of Securities Purchase Agreement",
"Form of Warrant"
03/03/2017 8-K Form 8-K - Current report
12/12/2016 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
10/20/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "# # #"
10/14/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors",
"Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors"
09/12/2016 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Indemnification Agreement"
08/10/2016 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "EMPLOYMENT AGREEMENT",
"EXHIBIT A",
"Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer SAN ANTONIO – Inspyr Therapeutics, Inc. , a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces the appointment of Ronald Shazer, M.D. as Senior Vice President and Chief Medical Officer effective immediately. Dr Shazer will lead the clinical development of mipsagargin. “Ron’ s experience in leading the development of novel oncology therapeutics makes him ideal to lead our development efforts at Inspyr Therapeutics,” said Chris Lowe, President and CEO of Inspyr Therapeutics. “Our near-term priority is to accelerate our clinical development activities and Ron’ s deep understanding of oncology will be a valuable addition to the orga..."
08/05/2016 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "Chris Lowe Employment Agreement",
"Chris Lowe Employment Agreement",
"Confidential Information and Invention Assignment Agreement",
"Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director SAN ANTONIO – Inspyr Therapeutics, Inc. , a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Christopher Lowe has been appointed President and Chief Executive Officer, and as a member of the Company’ s Board of Directors. Mr. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Company’ s Board of Directors since March 2016. “The Board is impressed with Chris’ ability to quickly grasp the significant potential of mipsagargin and develop a meaningful path forward for our Company,..."
08/02/2016 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation",
"GenSpera Announces Name Change to Inspyr Therapeutics SAN ANTONIO – GenSpera, Inc. , a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announces that it will change its corporate name to Inspyr Therapeutics, Inc. and will begin trading on the OTCQB under the ticker symbol NSPX effective August 2, 2016. The Company will also unveil a new corporate website at www.inspyrtx.com. “The changing of our corporate name is a first step in a number of upcoming actions that will define our path forward and our focus on building shareholder value,” said Peter E. Grebow, Ph.D., Interim Chairman. “Our new corporate name, Inspyr Therapeutics, reflects the significant potential we see with the novel prodrug mipsagargin and our Company’ s future poten..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy